DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Escitalopram for the Treatment of Depression in Alzheimer's Disease

Information source: Konkuk University Medical Center
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Alzheimer's Disease

Intervention: escitalopram (Drug); Placebo (Drug)

Phase: Phase 4

Status: Completed

Sponsored by: Konkuk University Medical Center

Official(s) and/or principal investigator(s):
Seol-Heui HAN, Professor, Principal Investigator, Affiliation: Kunkuk Universicy Hospital
Dong-Won YANG, Professor, Principal Investigator, Affiliation: Seoul St. Mary's Hospital
Sung-Yoon KIM, Professor, Principal Investigator, Affiliation: Asan Medical Center
Kun-Woo PARK, Professor, Principal Investigator, Affiliation: Korea University Hospital
Do-Hoon KIM, Professor, Principal Investigator, Affiliation: Hanlym University Hospital
So-Young MUN, Professor, Principal Investigator, Affiliation: AJU University Hospital

Summary

Purpose : to Evaluation of the Efficacy of Escitalopram for the Treatment of Depression in Alzheimer's Disease Trial Design : A 12-week, randomized, double-blind, parallel-group, placebo-controlled trial with an open-label, 12-week extension

Clinical Details

Official title: A 12-Week Randomized, Double-blind, Parallel-group, Placebo-controlled Trial With and Open-label, 12-week Extension, Multicenter to Evaluation of the Efficacy of Escitalopram for the Treatment of Depression in Alzheimer's Disease

Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment

Primary outcome: Change in CSDD(Cornell scale for depression in dementia) from baseline after 12 weeks of between treatment groups

Secondary outcome:

Change from baseline in CSDD(Cornell scale for depression in dementia) at week 4, 8, 16 and 24.

Change from baseline in K-MMSE at week 12 and 24.

Change from baseline in ADAS-Cog at week 12 and 24.

Change from baseline in NPIQ at week 12 and 24.

Change from baseline in S-IADL at week 12 and 24.

Change from baseline in GDS-15 at week 4, 8, 12, 16 and 24.

Change from baseline in CDR at week 12 and 24.

Change from baseline in CDR sum of box at week 12 and 24.

Change from baseline in Pittsburgh Sleep Quality Index at week 12 and 24.

Detailed description: Clinical trial agreement signed by the parties to the subjects through a process of screening. if it is consider suitable for evaluating through the selection / exclusion criteria, they will be randomly assigned to the test group or control group (placebo). Assigned to the test group or control subjects, they will be prescribe the 5mg Escitalopram or Placebo. without regard to meals, it will be taking once a day. and than It should be increased the capacity every two weeks by 5mg/day up to a maximum 15mg/day. and than, on the treatment for a 8 weeks, If you don't find the side effect, Maintaining the same capacity. If you find the side effect, you should lose capacity.(10mg/day) The test group or control subjects, will receive a doctor's examination and inspection through six visits for a 24weeks from the date of the randomly assigned participants.

Eligibility

Minimum age: 50 Years. Maximum age: N/A. Gender(s): Both.

Criteria:

Inclusion Criteria: 1) over the age of 50 2) Medical diagnostic criteria must meet the standard. 1. Subject diagnosed with Alzheimer's disease in accordance with NINCDS-ADRDA Criteria. 2. Subject with three or more symptoms of the Olin depression (major depressive episode) diagnostic criteria. 3. clinical dementia rating (CDR) of 0. 5 to 2 4. MMSE 10 ~ 26 (K-MMSE) 5. GDS-15 ≥ 5 points 3) When screening, Cholinesterase inhibitors taking a minimum of four weeks or more stable subject. 4) During the clinical trials, Subject does not change the capacity of Cholinesterase Inhibitors. 5) MRI or CT results within 24 months of subject with Alzheimer's disease (AD) 6) Participation in clinical trials to determine their own and written informed consent form and subject who actively perform clinical procedure including the questionnaire. But the subjects with cognitive dysfunction that cannot voluntarily make the decision, can be determined by an authorized representative to participate in. 7) Subjects must be accompanied their guardian to every visit. More than three days a week, more than 4 hours per day, spend the day with the guardian. Exclusion Criteria: 1. If you are taking other depression drugs within 4 weeks before the start of the clinical trials(e. g. SSRI, Stablon, TCA, wellbutrin, ixel) 2. If you have any other mental illness (bipolar disorder, schizophrenia, etc.) 3. If you have a serious medical illness (heart failure, angina pectoris, myocardial infarction, arteriosclerosis, etc.) or psychiatric illness. 4. Seizures, brain surgery, organic brain disease and history of organic affective disorder and at the brain MRI, abnormalities other than brain atrophy. 5. If you have a history of the test drug hypersensitivity 6. If you are taking memantin (dementia) 7. If you participated in another clinical trial within 3 months. 8. If pregnant or fertile women, who have not received sterilization or if you do not want to use an effective method of contraception. 9. In laboratory tests, if you have kidney failure or liver failure. 10. If you have history or habitual drinking or a history of drug abuse. 11. Uncontrolled diabetes or hypertension. 12. If determined to be inappropriate for clinical trials.

Locations and Contacts

MedicalExcellence, Seoul, Secho-gu banpo-dong 505, Korea, Republic of
Additional Information

Starting date: November 2011
Last updated: August 12, 2014

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017